Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083 3/07/2025

24,76 USD (-3,02%)

(-3,02%) 3/07/2025

Grafiek Nektar Therapeutics

Grafiek Nektar Therapeutics

1 dag1d -3,02%
1 week1w -3,88%
1 maand1m 3.217,70%
3 maanden3m 4.386,32%
6 maanden6m 2.016,24%
1 jaar1j 1.819,38%
5 jaar5j 3,25%

Nektar Therapeutics in het nieuws

Toon enkel gratis nieuws

13 mei 2025 · Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference · Persbericht

8 mei 2025 · Nektar Therapeutics Reports First Quarter 2025 Financial Results · Persbericht

2 mei 2025 · Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets · Persbericht

20 maart 2025 · Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference · Persbericht

12 maart 2025 · Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results · Persbericht

6 maart 2025 · Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets · Persbericht

3 september 2024 · Nektar Management to Present at Upcoming Investor Conferences · Persbericht

8 augustus 2024 · Nektar Therapeutics Reports Second Quarter 2024 Financial Results · Persbericht

2 augustus 2024 · Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets · Persbericht

12 juni 2024 · Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 · Persbericht

Profiel Nektar Therapeutics

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.nektar.com

Hoofdzetel: San Francisco, California Verenigde Staten

CEO: Howard Robin

Werknemers: 820

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe